Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2017.1324420
Abstract: ABSTRACT Introduction: The treatment of relapsed/refractory (RR) CLL has been revolutionized by the advent of the new oral inhibitors of B-cell receptor (BCR) signaling and the pro-survival protein, B-cell lymphoma 2 (BCL2). Additionally, new and… read more here.
Keywords: relapsed refractory; lymphocytic leukemia; pharmacotherapy relapsed; pharmacotherapy ... See more keywords